FDA Says Goodbye to Emergency Plasma Therapy for COVID Patients
Published Date: 10/2/2025
Notice
Summary
The FDA is ending the special emergency approval for using COVID-19 convalescent plasma as a treatment. This change affects healthcare providers and patients who used this plasma during the pandemic. The revocation means this treatment won’t be authorized anymore, but it won’t cost anyone extra or happen suddenly—it’s a clear update based on new information.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
EUA Revoked for COVID-19 Plasma
The FDA revoked the Emergency Use Authorization (EUA) for COVID-19 convalescent plasma. This means the plasma treatment is no longer authorized for use and the change affects healthcare providers and patients who used this plasma during the pandemic. The FDA stated the revocation will not impose extra costs on people and will not occur suddenly.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in